|
gptkbp:instanceOf
|
gptkb:biotechnology
gptkb:public_company
|
|
gptkbp:acquiredBy
|
gptkb:Semma_Therapeutics
gptkb:ViaCyte
|
|
gptkbp:businessModel
|
gptkb:company
|
|
gptkbp:CEO
|
gptkb:Reshma_Kewalramani
|
|
gptkbp:collaboratesWith
|
gptkb:Moderna
gptkb:CRISPR_Therapeutics
|
|
gptkbp:countryOfOperation
|
gptkb:United_States
|
|
gptkbp:focusesOn
|
rare diseases
cystic fibrosis treatments
|
|
gptkbp:foundedBy
|
gptkb:Joshua_Boger
|
|
gptkbp:foundedIn
|
gptkb:Cambridge,_Massachusetts,_United_States
|
|
gptkbp:foundedYear
|
1989
|
|
gptkbp:hasResearchCenter
|
gptkb:Australia
gptkb:Austria
gptkb:Belgium
gptkb:Boston,_Massachusetts
gptkb:Canada
gptkb:China
gptkb:Czech_Republic
gptkb:Denmark
gptkb:Finland
gptkb:France
gptkb:Germany
gptkb:Greece
gptkb:Hungary
gptkb:Ireland
gptkb:Italy
gptkb:Japan
gptkb:Netherlands
gptkb:Norway
gptkb:Poland
gptkb:Portugal
gptkb:Slovakia
gptkb:Slovenia
gptkb:Spain
gptkb:Sweden
gptkb:Switzerland
gptkb:Turkey
gptkb:San_Diego,_California
gptkb:Oxford,_United_Kingdom
gptkb:Milton_Park,_United_Kingdom
|
|
gptkbp:headquartersLocation
|
gptkb:Boston,_Massachusetts,_United_States
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Vertex Pharmaceuticals
|
|
gptkbp:industry
|
gptkb:biotechnology
|
|
gptkbp:listedOn
|
gptkb:NASDAQ
|
|
gptkbp:location
|
gptkb:Boston
gptkb:Massachusetts
|
|
gptkbp:marketCap
|
over $100 billion (2024)
|
|
gptkbp:netIncome
|
$3.3 billion (2023)
|
|
gptkbp:notableProduct
|
gptkb:Kalydeco
gptkb:Orkambi
gptkb:Symdeko
gptkb:Trikafta
|
|
gptkbp:numberOfEmployees
|
2023
over 4,000
|
|
gptkbp:researchInterest
|
pain management
gene editing
sickle cell disease
beta thalassemia
|
|
gptkbp:revenue
|
$9.8 billion (2023)
|
|
gptkbp:stockExchange
|
gptkb:NASDAQ-100
gptkb:S&P_500
|
|
gptkbp:stockSymbol
|
gptkb:VRTX
|
|
gptkbp:subsidiary
|
gptkb:Semma_Therapeutics
gptkb:ViaCyte
|
|
gptkbp:tradedOn
|
gptkb:NASDAQ:VRTX
|
|
gptkbp:website
|
https://www.vrtx.com/
|
|
gptkbp:bfsParent
|
gptkb:David_Altshuler
gptkb:Seaport_District
gptkb:Stuart_Schreiber
|
|
gptkbp:bfsLayer
|
4
|